熱門資訊> 正文
FDA批准Insulet的Omnipod 5治疗2型糖尿病
2024-08-27 05:26
- Insulet (NASDAQ:PODD) said it has received FDA clearance for its Omnipod 5 Automated Insulin Delivery, or AID, system for the treatment of type 2 diabetes in adults.
- The company said the clearance makes Omnipod 5 the only AID system approved for both type 1 and type 2 diabetes management.
More on Insulet
- Insulet Corporation 2024 Q2 - Results - Earnings Call Presentation
- Insulet Corporation (PODD) Q2 2024 Earnings Call Transcript
- Insulet Corporation: Insulin Pump Provider Fighting Back After Torrid 2023
- Insulet Q2 2024 Earnings Preview
- Insulet's prelim Q2 revenue tops estimates
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
